CLINICAL_TRIALS
trial_result
· 2021-09-14
Clinical Trial Update: Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) [Phase 1, Phase 2]
Summary
Phase 1/2 trial exploring PPAR-γ agonists for immunomodulation and vascular prevention in systemic lupus erythematosus has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-14